Author: Mitchell Gaydash
How a GIVIMP Certification Program Can Increase Confidence in In Vitro Methods
April 20, 2021Regulatory bodies, validation authorities, method developers, and industry toxicologists realize the need to increase confidence in the scientific validity of novel in vitro methods – especially those being proposed for regulatory application ....
IIVS Co-Publishes Article on Ocular Animal Model Alternatives
April 20, 2021The human eye may be exposed to chemicals through various situations, such as accidental splashing or exposure to chemical particles, vapours or gases. Workers and consumers are usually advised to immediately wash eyes generously with water following exposure....
IIVS to collaborate with RIFM to develop non-animal technologies for respiratory allergy
March 31, 2021The Institute for In Vitro Sciences (IIVS) and the Research Institute for Fragrance Materials (RIFM) announce a collaboration to develop a non-animal (in vitro) test designed to assess potential respiratory allergens....
China to Exempt Animal Testing for Imported General Cosmetics on May 1
March 4, 2021IIVS is pleased to see China providing a pathway for the importation of certain cosmetics without #animaltesting. The pathway does contain certain requirements that the international community must strive to meet - but it is certainly a major step forward. IIVS will continue its outreach with China's National Institute for Food and Drug Control (NIFDC), as well as with provincial FDA's, to continue to implement #nonanimal methods into their regulatory guidelines. Thank you to all our great contributors who fund this important work!...
Acute Electronic Vapour Product Whole Aerosol Exposure of 3D Human Bronchial Tissue
March 2, 2021IIVS is excited to have taken part in a new publication highlighting the use of non-animal methods to compare cellular and molecular responses of tobacco smoke and Electronic Vapor Product aerosols. Read and Download the open access article here....
Validation of the 3D RSMN Assay
February 10, 2021IIVS is excited to have taken part in the validation of the Reconstructed Skin Micronucleus Assay as a big step towards the establishment of an OECD test guideline. Read the Full Article Here...
IIVS e-News – October 2020
September 28, 2020IIVS is pleased to announce that Allison Hilberer will participate in the OECD Test Guidelines Programme Expert Groups (OECD TG EG) for eye and skin irritation, phototoxicity and skin sensitization. Allison is a Toxicologist II and Study Director at IIVS where she oversees the conduct of in vitrostudies in these areas. Allison has also been involved in many validation programs and participated in efforts to draft and revise OECD Test Guidelines. Read Post...
IIVS, RIFM and Shiseido Partner to Transfer Non-animal Photosafety Tests
July 14, 2020The Institute for In Vitro Sciences (IIVS) has entered into an agreement with Shiseido and the Research Institute for Fragrance Materials (RIFM) to support the technology transfer of non-animal tests for photosafety testing. The program aims to build upon IIVS’ current photosafety tiered testing program, which addresses photoirritation, through the development of additional testing strategies to identify photoallergens. Both photoirritation and photoallergenicity are important in the safety assessment of fragrances. RIFM, Shiseido, and IIVS share the common goal of promoting the...
Webinar : Use of Non-animal Skin Sensitization Methods
June 3, 2020A recorded webinar on the "Use of Non-animal Skin Sensitization Methods" by IIVS’s Hans Raabe and US EPA's Gino Scarano and James Cox is now available for viewing at https://www.piscltd.org.uk/nam-webinars/. The webinar reviews the status of Non-Animal methods acceptance of skin sensitization testing within the EPA framework as well as an overview of several assays that can be used to evaluate this endpoint. Slides of the presentation are also available for download as well....
Services and Tools for COVID-19 Drug Development
May 21, 2020IIVS provides robust test systems and assays to detect the adverse effects of diverse materials, including pharmaceuticals targeting COVID-19. The IIVS Respiratory Toxicology Program offers testing services using cutting edge 3D pulmonary models - in addition to human 2D primary cells and lines - such as reconstructed human airways and human precision-cut human lung slices (hPCLS) that contain multiple cell types including immune competent macrophages. These systems, combined with our advanced exposure techniques, allow the detection of acute toxic responses...